Skip to main content
SpringerLink
Log in

Liver Tumors

  • Chapter
Cancer in Adolescents and Young Adults

Part of the book series: Pediatric Oncology ((PEDIATRICO))

  • 1306 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bleyer A, O’Leary M, Barr R, Ries LAG (eds) (2006) Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975–2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD, p 220

    Google Scholar 

  2. Bosch FX, Ribes J, Borras J (1999) Epidemiology of primary liver cancer. Semin Liver Dis 19:271–285

    PubMed  CAS  Google Scholar 

  3. Feraly J, Parkin DM, Pisani P (1998) GLOBOCAN Graphical Package 1: Cancer Incidence and Mortality Worldwide. IARC Press, Lyons

    Google Scholar 

  4. Chen JC, et al (1998) Hepatocellular carcinoma in children: clinical review and comparison with adult cases. J Pediatr Surg 33:1350–1354

    PubMed  CAS  Google Scholar 

  5. Czauderna P (2002) Adult type vs. childhood hepatocellular carcinoma — are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med Pediatr Oncol 39:19–23

    Google Scholar 

  6. Di Bisceglie AM, et al (1998) NIH conference. Hepatocellular carcinoma. Ann Intern Med 108:390–401

    Google Scholar 

  7. Chang M, et al (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336:1855–1859

    PubMed  CAS  Google Scholar 

  8. Ishak KG (1991) Hepatocellular carcinoma associated with inherited metabolic diseases. In: Tabor E, Di Bisceglie AM, Purcell RH (eds) Etiology, Pathogenesis and Treatment of Hepatocellular Carcinoma in North America. Portfolio Publishing Company, The Woodlands, Texas, pp 91–103

    Google Scholar 

  9. Ugarte N, Gonzalez-Crussi F (1981) Hepatoma in siblings with progressive familial cholestatic cirrhosis of childhood. Am J Clin Pathol 76:172–177

    PubMed  CAS  Google Scholar 

  10. Kharsa D, et al (1990) Adenome hepatique et carcinome hepatocellulaire chez deux freres ateints de glycogenose de type I. Gastroenterol Clin Biol 14:84–89

    PubMed  CAS  Google Scholar 

  11. Eriksson S, Carlson J, Velez R (1986) Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 296:1411–1412

    Google Scholar 

  12. Ishak KG (1979) Hepatic neoplasms associated with contraceptives and anabolic steroids. Recent Results Cancer Res 66:73–128

    PubMed  CAS  Google Scholar 

  13. Sun Z, Lu P, Gail MH (1999) Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable aflatoxin metabolite M1. Hepatology 30:379–383

    PubMed  CAS  Google Scholar 

  14. Christopherson WM, Mays ET (1987) Risk factors, pathology, and pathogenesis of selected benign and malignant liver neoplasm. In: Wanebo HH (ed) Hepatic and Biliary Cancer. Marcel Decker, New York, pp 17–43

    Google Scholar 

  15. Okuda K (2000) Hepatocellular carcinoma. Hepatology 32:225–237

    CAS  Google Scholar 

  16. Okuda K (2002) Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangio-carcinoma variants. J Gastroenterol Hepatol 17:401–405

    PubMed  Google Scholar 

  17. Lauwers GY, et al (2002) Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 26:25–34

    PubMed  Google Scholar 

  18. Edmonson H (1956) Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. Arch Dis Child 1:168–186

    Google Scholar 

  19. Craig JR, et al (1980) Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 46:372–379

    PubMed  CAS  Google Scholar 

  20. McLarney JK, et al (1999) Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics 19:453–471

    PubMed  CAS  Google Scholar 

  21. Cheuk W, Chan JK (2001) Clear cell variant of fibrolamellar carcinoma of the liver. Arch Pathol Lab Med 125:1235–1238

    PubMed  CAS  Google Scholar 

  22. Berman MA, Burham JA, Sheahan DG (1988) Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and review of the literature. Hum Pathol 19:784–794

    PubMed  CAS  Google Scholar 

  23. Van Eyken P, et al (1990) Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. Histopathology 17:101–107

    PubMed  Google Scholar 

  24. Seitz G, et al (2002) Adult-type hepatocellular carcinoma in the center of a fibrolamellar hepatocellular carcinoma. Hum Pathol 33:765–769

    PubMed  Google Scholar 

  25. Paradinas FJ, et al (1982) High serum vitamin B12 binding capacity as a marker of fibrolamellar variant of hepatocellular carcinoma. Br Med J 25:840–842

    Google Scholar 

  26. Sheppard KJ, et al (1983) High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J 286:57

    CAS  Google Scholar 

  27. Wheeler K, et al (1986) Transcobalamin I as a “marker” for fibrolamellar hepatoma. Med Pediatr Oncol 114:227–229

    PubMed  CAS  Google Scholar 

  28. Kane SP, et al (1978) Vitamin B12 binding protein as a tumour marker for hepatocellular carcinoma. Gut 19:1105–1109

    PubMed  CAS  Google Scholar 

  29. Collier NR, et al (1984) Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet 1:538–540

    PubMed  CAS  Google Scholar 

  30. Hany MA, et al (1997) A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype. Med Pediatr Oncol 28:136–138

    PubMed  CAS  Google Scholar 

  31. Sirivatanauksorn Y, et al (2001) Genomic homogeneity in fibrolamellar carcinomas. Gut 49:82–86

    PubMed  CAS  Google Scholar 

  32. Wilkens L, et al (2000) Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization. J Clin Pathol 114:867–874

    CAS  Google Scholar 

  33. Prokurat A, et al (2002) Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing betacatenin. Med Pediatr Oncol 39:510–518

    PubMed  Google Scholar 

  34. Perilongo G, Plaschkes J, Zimmermann A (2002) Hepatic tumours. In: Souhami RL, Tannock I, Hohenberger P, Horiot JC (eds) Oxford Textbook of Oncology, Vol. 2. Oxford University Press, Oxford, pp 2657–2668

    Google Scholar 

  35. Rowland JM (2002) Hepatoblastoma: assessment of criteria for histologic classification. Med Pediatr Oncol 39:478–483

    PubMed  Google Scholar 

  36. Buendia MA (2002) Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol 39:530–535

    PubMed  Google Scholar 

  37. Zimmermann A (2002) Pediatric liver tumors and hepatic ontogenesis: common and distinctive pathways. Med Pediatr Oncol 39:492–503

    PubMed  Google Scholar 

  38. Postovsky S, et al (2001) Late recurrence of combined hepatocellular carcinoma and hepatoblastoma in a child: case report and review of the literature. Eur J Pediatr Surg 11:61–65

    PubMed  CAS  Google Scholar 

  39. Dumortier J, et al (1999) Recurrence of hepatocellular carcinoma as a mixed hepatoblastoma after liver transplantation. Gut 45:622–625

    PubMed  CAS  Google Scholar 

  40. Chen TC, Hsieh LL, Kuo TT (1995) Absence of p53 gene mutation and infrequent overexpression of p53 protein in hepatoblastoma. J Pathol 176:243–247

    PubMed  CAS  Google Scholar 

  41. Kusafuka T, et al (1997) Mutation analysis of p53 gene in childhood malignant solid tumors. J Pediatr Surg 32:1175–1180

    PubMed  CAS  Google Scholar 

  42. Pang A, et al (2003) Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genet Cytogenet 146:8–15

    PubMed  CAS  Google Scholar 

  43. Aoki T, et al (2004) Clinical value of alterations in p73 gene, related to p53 at 1p36, in human hepatocellular carcinoma. Int J Oncol 24:441–446

    PubMed  CAS  Google Scholar 

  44. Feitelson MA, et al (2002) Genetic mechanisms of hepatocarcinogenesis. Oncogene 21:2593–2604

    PubMed  CAS  Google Scholar 

  45. Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nature Genet 31:339–346

    PubMed  CAS  Google Scholar 

  46. Van Tornout JM, Buckley JD, Ortega JA (1997) Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children’s Cancer Group. J Clin Oncol 15:1190–1197

    PubMed  Google Scholar 

  47. Tsuchida Y, et al (1989) Three different types of alpha-fetoprotein in the diagnosis of malignant solid tumors: use of a sensitive lectin-affinity immunoelectrophoresis. J Pediatr Surg 24:350–355

    PubMed  CAS  Google Scholar 

  48. Ortega JA, Siegel SE (1993) Biological markers in pediatric solid tumors. In: Pizzo AP, Poplack DG (eds) Principles and Practice of Pediatric Oncology. Lippincott, Philadelphia pp 179–194

    Google Scholar 

  49. Miller JH, Gates GH, Stanley P (1977) The radiologic investigation of hepatic tumors in childhood. Radiology 124:451–464

    PubMed  CAS  Google Scholar 

  50. Liu P, Daneman A, Stringer DA (1985) Diagnostic imaging of liver masses in children. J Can Assoc Radiol 36:296–300

    PubMed  CAS  Google Scholar 

  51. de Campo M. de Campo JF (1988) Ultrasound of primary hepatic tumours in childhood. Pediatr Radiol 19:19–24

    PubMed  Google Scholar 

  52. King S, et al (1993) Value of CT in determining the resectability of hepatoblastoma before and after chemotherapy. AJR Am J Roentgenol 160:793–799

    PubMed  CAS  Google Scholar 

  53. Korobkin M, et al (1981) Computed tomography of primary liver tumors in children. Radiology 139:431–438

    PubMed  CAS  Google Scholar 

  54. Boechat MI, et al (1988) Primary liver tumors in children: comparison of CT and MR imaging. Radiology 169:727–732

    PubMed  CAS  Google Scholar 

  55. Stocker JT, Ishak KG (1978) Undifferentiated embryonal sarcoma of the liver. Report of 31 cases. Cancer 42:336–348

    PubMed  CAS  Google Scholar 

  56. Chowdhary SK, et al (2004) Undifferentiated embryonal sarcoma in children: beware of the solitary liver cyst. J Pediatr Surg 39:E9–12

    PubMed  CAS  Google Scholar 

  57. Bisogno G, et al (2002) Undifferentiated embryonal sarcoma of the liver in childhood: a curable disease. Cancer 94:252–257

    PubMed  Google Scholar 

  58. Uchiyama M, et al. (2001) Treatment of ruptured undifferentiated sarcoma of the liver in children. J Hepatobil Pancreat Surg 8:87–91

    CAS  Google Scholar 

  59. Herman P et al. (2000) Hepatic Adenoma and focal nodular hyperplasia: differential diagnosis and treatment. World J Surg 24:372–376

    PubMed  CAS  Google Scholar 

  60. Heaton ND, et al (1991) Focal nodular hyperplasia of the liver: a link with sickle cell disease. Arch Dis Child 66:1073–1074

    PubMed  CAS  Google Scholar 

  61. Bouyn CL, et al (2003) Hepatic focal nodular hyperplasia in children previously treated for a solid tumour. Incidence risk factors and outcome. Cancer 97: 3103–3107

    Google Scholar 

  62. Reymond D, et al (1995) Focal nodular hyperplasia of the liver in children. Review of follow up and outcome. J Pediatr Surg 30:1590–1593

    PubMed  CAS  Google Scholar 

  63. Reynolds M (1999) Pediatric liver tumors. Semin Surg Oncol 16:159–172

    PubMed  CAS  Google Scholar 

  64. Evans AE, Land VJ, Newton WA Jr (1982) Combination chemotherapy in the treatment of children with malignant hepatoma. Cancer 50:821–826

    PubMed  CAS  Google Scholar 

  65. Ortega JA, et al (1991) Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Children’s Cancer Study Group. J Clin Oncol 9:2167–2176

    PubMed  CAS  Google Scholar 

  66. MacKinlay G, Pritchard J (1992) A common language for childhood liver tumours. Pediatr Surg Int 7:325–326

    Google Scholar 

  67. Brown J, et al (2000) Pretreatment prognostic factors for children with hepatoblastoma — results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 36:1418–1425

    PubMed  CAS  Google Scholar 

  68. The Cancer of the Liver Italian Program (CLIP) Investigators (2000) CLIP, Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31:840–845

    Google Scholar 

  69. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the Bclc staging classification. Semin Liver Dis 19:329–338

    PubMed  CAS  Google Scholar 

  70. Leung TW, et al (2002) Construction of the Chinese University prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the cancer of the liver Italian program staging system: a study based on 926 patients. Cancer 94:1760–1769

    PubMed  Google Scholar 

  71. The Liver Cancer Study Group of Japan (1994) Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 74: 2272–2280

    Google Scholar 

  72. Pugh RNH, et al (1973) Transection of the oesophagus for bleeding of oesophageal varices. Br J Surg 60:646–664

    PubMed  CAS  Google Scholar 

  73. Tagge EP, et al (1992) Resection including transplantation for hepatoblastoma and hepatocellular carcinoma. J Pediatr Surg 21:292–297

    Google Scholar 

  74. Katzenstein HM, et al (2002) Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group intergroup study. J Clin Oncol 20:2789–2797

    PubMed  Google Scholar 

  75. Reyes JD, et al (2000) Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr 136:795–804

    PubMed  CAS  Google Scholar 

  76. Koneru B, et al (1991) Liver transplantation for hepatoblastoma. The American experience. Ann Surg 213:118–121

    PubMed  CAS  Google Scholar 

  77. Otte JB, et al (2004) Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 42:74–83

    PubMed  CAS  Google Scholar 

  78. Chang MH (2003) Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. Liver Int 23:309–314

    PubMed  Google Scholar 

  79. Bruix J, et al (2001) Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 35:421–430

    PubMed  CAS  Google Scholar 

  80. Sakamoto M, Hirohashi S (1998) Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection o percutaneous ethanol injection. Jpn J Clin Oncol 28:604–608

    PubMed  CAS  Google Scholar 

  81. Takayama K, et al (1998) Early hepatocellular carcinomas an entity with high rate of surgical cure. Hepatology 28:1241–1246

    PubMed  CAS  Google Scholar 

  82. Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 39:1434–1440

    Google Scholar 

  83. Mazzaferro V, et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699

    PubMed  CAS  Google Scholar 

  84. Jonas S, et al (2001) Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33:1080–1086

    PubMed  CAS  Google Scholar 

  85. Yao FY, et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of tumor size limits does not adversely impact survival. Hepatology 33:1394–1403

    PubMed  CAS  Google Scholar 

  86. Yao FY, et al (2002) Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 8:873–883

    PubMed  Google Scholar 

  87. Cronin D, Millis M, Siegler M (2001) Transplantation of liver grafts from living donors into adults: too much, too soon? N Engl J Med 344:1633–1637

    PubMed  Google Scholar 

  88. Sarasin F, et al (2001) Liver donor liver transplantation for early hepatocellular carcinoma: a cost-effective perspective. Hepatology 33:1073–1079

    PubMed  CAS  Google Scholar 

  89. Trotter J, et al (2002) Adult-to-Adult transplantation of the right hepatic lobe from living donor. N Engl J Med 14:1074–1082

    Google Scholar 

  90. Lau WY, et al (2003) Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 237:171–179

    PubMed  CAS  Google Scholar 

  91. Lencioni R, et al (2004) Percutaneous ablation of hepatocellular carcinoma: state-of-the-art. Liver Transpl 10: S91–97

    PubMed  Google Scholar 

  92. Livraghi T, et al (2004) Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl 10:S98–106

    PubMed  Google Scholar 

  93. Livraghi T (2003) Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma. J Hepatobil Pancreat Surg 10:67–76

    Google Scholar 

  94. Okada S (1999) Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis 19:323–328

    PubMed  CAS  Google Scholar 

  95. Buscarini L, Buscarini E, Di Stasi M (2001) Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol 11:914–921

    PubMed  CAS  Google Scholar 

  96. Lencioni RA, et al (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 228:235–240

    PubMed  Google Scholar 

  97. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442

    PubMed  CAS  Google Scholar 

  98. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261

    Google Scholar 

  99. Zhang Z, et al (2000) The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer 89:2606–2612

    PubMed  CAS  Google Scholar 

  100. Bruix J, et al (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27:1578–1583

    PubMed  CAS  Google Scholar 

  101. Lo CM, et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171

    PubMed  CAS  Google Scholar 

  102. Raoul JL, et al (1997) Prospective randomized trial of chemoembolization versus intra-arterial injection of 131-I labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26:1156–1161

    PubMed  CAS  Google Scholar 

  103. Soini Y, et al (1996) Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol 49:470–473

    PubMed  CAS  Google Scholar 

  104. Huang CC, et al (1992) Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84:262–264

    PubMed  CAS  Google Scholar 

  105. Chou YY, et al (1997) Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. J Gastroenterol Hepatol 12:569–575

    PubMed  CAS  Google Scholar 

  106. Johnson PJ, et al (1978) Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet 1:1006–1009

    PubMed  CAS  Google Scholar 

  107. Chlebowski RT, et al (1984) Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Reports 68:487–491

    CAS  Google Scholar 

  108. Hochster HS, et al (1985) 4’Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 3:1535–1540

    PubMed  CAS  Google Scholar 

  109. Dunk AA, et al (1985) Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study. J Hepatol 1:395–404

    PubMed  CAS  Google Scholar 

  110. Vogel CL, et al (1977) A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer 39:1923–1929

    PubMed  CAS  Google Scholar 

  111. Falkson G, et al (1978) Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 42:2149–2156

    PubMed  CAS  Google Scholar 

  112. Tetef M, et al (1995) 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 13:460–463

    PubMed  CAS  Google Scholar 

  113. Porta C, et al (1995) 5-Fluorouracil and D,L-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: a preliminary results of a phase II study. Oncology 52:487–491

    PubMed  CAS  Google Scholar 

  114. Melia WM, Westaby D, Williams R (1981) Diamminodichloride platinum (cis-platinum) in the treatment of hepatocellular carcinoma. Clin Oncol 7:275–280

    PubMed  CAS  Google Scholar 

  115. Okada S, et al (1993) A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 50:22–26

    PubMed  CAS  Google Scholar 

  116. Melia WM, Johnson PJ, Williams R (1983) Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 51:206–210

    PubMed  CAS  Google Scholar 

  117. Wierzbicki R, et al (1994) Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma. Ann Oncol 5:466–467

    PubMed  CAS  Google Scholar 

  118. Lozano RD, et al (2000) Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangio-carcinoma, and gallbladder cancer). Proc Am Soc Clin Oncol 19:264a (abstract 1025)

    Google Scholar 

  119. Yang TS, et al (2000) Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 89:750–756

    PubMed  CAS  Google Scholar 

  120. Kubicka S, et al (2001) Phase II study of sytemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 48:783–789

    PubMed  CAS  Google Scholar 

  121. Chao Y, et al (1998) Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 78:34–39

    PubMed  CAS  Google Scholar 

  122. O’Reilly EM, et al (2001) A phase II study of irinotecan in patients with advance hepatocellular carcinoma. Cancer 91:101–105

    PubMed  CAS  Google Scholar 

  123. Patt YZ, et al (2003) Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 21:421–427

    PubMed  CAS  Google Scholar 

  124. Ji SK, et al (1996) Combined cis-platinum and alpha interferon therapy of advanced hepatocellular carcinoma. Korean J Int Med 11:58–68

    CAS  Google Scholar 

  125. Falkson G, et al (1987) A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 60:2141–2145

    PubMed  CAS  Google Scholar 

  126. Falkson G, et al (1984) Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer 54:970–977

    PubMed  CAS  Google Scholar 

  127. Al-Idrissi HY, et al (1985) Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, adriamycin and mitomycin-C Hepatogastroenterology 32:8–10

    PubMed  CAS  Google Scholar 

  128. Bobbio-Pallavicini E, et al (1997) Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer 33:1784–1788

    PubMed  CAS  Google Scholar 

  129. Baker LH, et al (1977) Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study. Cancer Treat Reports 61:1595–1597

    CAS  Google Scholar 

  130. Taieb J, et al (2003) Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 98:2664–2670

    PubMed  CAS  Google Scholar 

  131. Patt YZ, et al (1998) Systemic therapy with platinol, interferon alpha 2b, doxorubicin and 5-fluorouracil (PIAF) for treatment of non-resectable hepatocellular carcinoma. Proc Am Soc Clin Oncol 17:301a (abstract 1158)

    Google Scholar 

  132. Leung TW, et al (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676–1681

    PubMed  CAS  Google Scholar 

  133. Minischetti M, et al (2000) TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically. Br J Cancer 109:829–837

    CAS  Google Scholar 

  134. Lai CL, et al (1989) Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 60:928–33

    PubMed  CAS  Google Scholar 

  135. Browder T, et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886

    PubMed  CAS  Google Scholar 

  136. Schwartz JD, et al (2002) Thalidomide in hepatocellular carcinoma (HCC) with optional interferon-alpha upon progression. Proc Am Soc Clin Oncol 21:10b

    Google Scholar 

  137. Schwartz JD, et al (2005) Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein. Program and abstracts of the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium; January 27–29, 2005; Hollywood, Florida. Abstract 134

    Google Scholar 

  138. Nagasue N, et al (1985) Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology 89:643–647

    PubMed  CAS  Google Scholar 

  139. Nagasue N, et al (1986) Estrogen receptors in hepatocellular carcinoma. Cancer 57:87–91

    PubMed  CAS  Google Scholar 

  140. Chow PK, et al (2002) High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 3:1221–1226

    Google Scholar 

  141. Perrone F, et al (2002) Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicenter randomised controlled trial. Curr Pharm Des 8:1013–1019

    PubMed  CAS  Google Scholar 

  142. Czauderna P, et al (2002) Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 20:2798–2804

    PubMed  CAS  Google Scholar 

  143. Exelby PR, et al (1975) Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics surgical section survey — 1974. J Pediatr Surg 10:329–337

    PubMed  CAS  Google Scholar 

  144. Haas JE, et al (1989) Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer 64:1082–1095

    PubMed  CAS  Google Scholar 

  145. Lack EE, Neave C, Vawter GF (1983) Hepatocellular carcinoma: review of 32 cases in childhood and adolescents. Cancer 52:1510–1515

    PubMed  CAS  Google Scholar 

  146. Farhi DC, et al (1983) Hepatocellular carcinoma in young adults. Cancer 52:1516–1525

    PubMed  CAS  Google Scholar 

  147. Craig J, et al (1980) Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 46:372–379

    PubMed  CAS  Google Scholar 

  148. Epstein BE, et al (1999) Metastatic nonresectable fibrolamellar hepatocellular carcinoma: prognostic features and natural history. Am J Clin Pathol 22:22–28

    CAS  Google Scholar 

  149. Saab S, Yao F (1996) Fibrolamellar hepatocellular carcinoma: case reports and a review of the literature. Digest Dis Sic 41:1981–1985

    CAS  Google Scholar 

  150. Altmann HW (1990) Some histological remarks on the fibrolamellar carcinoma of the liver. Pathol Res Pract 186:63–69

    PubMed  CAS  Google Scholar 

  151. Rolfes DB (1987) Fibrolamellar carcinoma of the liver. In: Okuda K, Ishak KG (eds) Neoplasms of the Liver. Springer, New York, NY, pp 137–142

    Google Scholar 

  152. Katzenstein HM, et al (2003) Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 97:2006–2012

    PubMed  Google Scholar 

  153. Holladay ES, et al (1985) Conversion to resectability by intra-arterial infusion chemotherapy after failure of systemic chemotherapy. J Pediatr Surg 20:715–717

    Google Scholar 

  154. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261

    Google Scholar 

  155. Rose DM, et al (1999) Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma. Am J Surg 177:405–410

    PubMed  CAS  Google Scholar 

  156. Malogolowkin MH, et al (2000) Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol 18:1279–1284

    PubMed  CAS  Google Scholar 

  157. Goiter S, et al (1987) Intraarterial chemotherapy with lipid contrast medium for hepatic malignancies in infants. Cancer 60:2886–2890

    Google Scholar 

  158. Ogita S, et al (1987) Intraarterial injection of anti-tumor drugs dispersed in lipid contrast medium: a choice for initially unresectable hepatoblastoma in infants. J Pediatr Surg 22:412–414

    PubMed  CAS  Google Scholar 

  159. Sue K, et al (1989) Intrahepatic arterial injections of cisplatin-phosphatidylcholine-Lipiodol suspension in two unresectable hepatoblastoma cases. Med Pediatr Oncol 17:496–500

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Hematology/Oncology, Keck School Of Medicine of USC, 4650 Sunset Blvd., Los Angeles, CA, 90027, USA

    Marcio H. Malogolowkin M.D.

  2. University of Bern, Murtenstraße 31, 3010, Bern, Switzerland

    Arthur Zimmermann M.D.

  3. Dept. of Pediatric Sugery, University Children’s Hospital, Bern, Switzerland

    Jack Plaschkes M.D.

Authors
  1. Marcio H. Malogolowkin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arthur Zimmermann M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jack Plaschkes M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. St. Charles Medical Center, Bend, Oregon, USA

    W. Archie Bleyer

  2. McMaster University, Hamilton, Ontario, Canada

    Ronald D. Barr

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Malogolowkin, M.H., Zimmermann, A., Plaschkes, J. (2007). Liver Tumors. In: Bleyer, W.A., Barr, R.D. (eds) Cancer in Adolescents and Young Adults. Pediatric Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68152-6_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-68152-6_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40842-0

  • Online ISBN: 978-3-540-68152-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation